Camurus AB (publ)

LSE:0RD1 Stock Report

Market Cap: SEK 36.9b

Camurus Valuation

Is 0RD1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RD1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 0RD1 (SEK631) is trading below our estimate of future cash flow value (SEK1252.33)

Significantly Below Future Cash Flow Value: 0RD1 is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RD1?

Key metric: As 0RD1 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0RD1. This is calculated by dividing 0RD1's market cap by their current earnings.
What is 0RD1's PE Ratio?
PE Ratio54.4x
EarningsSEK 678.17m
Market CapSEK 36.93b

Price to Earnings Ratio vs Peers

How does 0RD1's PE Ratio compare to its peers?

The above table shows the PE ratio for 0RD1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average20x
HIK Hikma Pharmaceuticals
11x7.43%UK£3.2b
HCM HUTCHMED (China)
4.4x-66.72%UK£1.5b
ANCR Animalcare Group
45.3x10.45%UK£230.3m
HLN Haleon
19.3x6.26%UK£32.5b
0RD1 Camurus
55.4x34.35%SEK 36.9b

Price-To-Earnings vs Peers: 0RD1 is expensive based on its Price-To-Earnings Ratio (55.4x) compared to the peer average (20x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does 0RD1's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0RD1 54.4xIndustry Avg. 21.3xNo. of Companies8PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0RD1 is expensive based on its Price-To-Earnings Ratio (55.4x) compared to the European Pharmaceuticals industry average (21.3x).

Price to Earnings Ratio vs Fair Ratio

What is 0RD1's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RD1 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio54.4x
Fair PE Ratio40.8x

Price-To-Earnings vs Fair Ratio: 0RD1 is expensive based on its Price-To-Earnings Ratio (55.4x) compared to the estimated Fair Price-To-Earnings Ratio (40.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RD1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 625.03
SEK 776.75
+24.27%
10.27%SEK 914.00SEK 650.00n/a8
Jul ’27SEK 577.00
SEK 769.50
+33.36%
10.86%SEK 914.00SEK 630.00n/a8
Jun ’27SEK 518.56
SEK 770.13
+48.51%
11.14%SEK 914.00SEK 620.00n/a8
May ’27SEK 530.55
SEK 770.13
+45.16%
11.80%SEK 930.00SEK 610.00n/a8
Apr ’27SEK 486.35
SEK 768.00
+57.91%
12.54%SEK 930.00SEK 610.00n/a7
Mar ’27SEK 496.93
SEK 768.00
+54.55%
12.54%SEK 930.00SEK 610.00n/a7
Feb ’27SEK 669.16
SEK 814.17
+21.67%
11.49%SEK 980.00SEK 660.00n/a6
Jan ’27SEK 617.00
SEK 793.71
+28.64%
11.56%SEK 980.00SEK 660.00n/a7
Dec ’26SEK 606.65
SEK 800.86
+32.01%
11.04%SEK 980.00SEK 660.00n/a7
Nov ’26SEK 627.25
SEK 823.83
+31.34%
16.55%SEK 1,116.00SEK 690.00n/a6
Oct ’26SEK 690.50
SEK 832.17
+20.52%
16.22%SEK 1,116.00SEK 690.00n/a6
Sep ’26SEK 717.00
SEK 832.17
+16.06%
16.22%SEK 1,116.00SEK 690.00n/a6
Aug ’26SEK 668.50
SEK 832.17
+24.48%
16.22%SEK 1,116.00SEK 690.00n/a6
Jul ’26SEK 602.58
SEK 786.14
+30.46%
18.97%SEK 1,116.00SEK 600.00SEK 577.007
Jun ’26SEK 509.24
SEK 734.57
+44.25%
8.92%SEK 835.00SEK 600.00SEK 518.567
May ’26SEK 621.00
SEK 737.29
+18.73%
8.78%SEK 844.00SEK 610.00SEK 530.557
Apr ’26SEK 580.50
SEK 758.50
+30.66%
5.49%SEK 844.00SEK 715.00SEK 486.356
Mar ’26SEK 664.67
SEK 757.67
+13.99%
5.61%SEK 844.00SEK 710.00SEK 496.936
Feb ’26SEK 596.00
SEK 745.00
+25.00%
2.77%SEK 768.00SEK 710.00SEK 669.166
Jan ’26SEK 563.85
SEK 745.00
+32.13%
2.77%SEK 768.00SEK 710.00SEK 617.006
Dec ’25SEK 564.50
SEK 745.00
+31.98%
2.77%SEK 768.00SEK 710.00SEK 606.656
Nov ’25SEK 597.50
SEK 753.33
+26.08%
1.72%SEK 773.00SEK 730.00SEK 627.256
Oct ’25SEK 651.00
SEK 742.67
+14.08%
2.77%SEK 770.00SEK 710.00SEK 690.506
Sep ’25SEK 712.50
SEK 742.67
+4.23%
2.77%SEK 770.00SEK 710.00SEK 717.006
Aug ’25SEK 687.50
SEK 742.67
+8.02%
2.77%SEK 770.00SEK 710.00SEK 668.506
Jul ’25SEK 603.01
SEK 621.50
+3.07%
9.35%SEK 690.00SEK 500.00SEK 602.586
SEK 776.75
Fair Value
18.8% undervalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/22 16:01
End of Day Share Price 2026/07/21 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Camurus AB (publ) is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB
Gonzalo Artiach CastanonDanske Bank
Kristofer Liljeberg-SvenssonDNB Carnegie